Kyoto iCAP invests additional USD 1 million in RegCell within USD 40 million round

• Kyoto University Innovation Capital made an additional investment in RegCell as part of a USD 40 million private financing round.
• RegCell is a Kyoto University spinout developing antigen-specific regulatory T-cell therapies based on research by immunologist Shimon Sakaguchi.
• The company is advancing its S/F-iTreg approach, aiming to restore immune tolerance in autoimmune diseases through cell therapy.
• RegCell is headquartered in Emeryville, California, led by CEO Michael V. McCullar.
• The fund’s follow-on commitment totaled about USD 1 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyoto University Innovation Capital Co Ltd published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein.